| |
Thursday, April 6, 2023 | 11am ET / 8am PT In this webinar, we show how we used Nunchuck to make LNPs in small-volume screening runs and bulk formulations. The complete workflow will be illustrated, from the testing of flow rates in initial formulations to the final assessment of mRNA expression in multiple cell types, showing successful transfection of cells by the LNPs. Register now.
|
|
Today's Big NewsMar 29, 2023 |
|
April 3 - 4, 2023 | San Diego, CA Be a part of a learning experience developed by our esteemed Advisory Board who are leaders in the life science communications space. Time is running out! Register Today
|
|
| By Max Bayer Johnson & Johnson is 'exiting' a late-stage respiratory syncytial virus program amid a large-scale overhaul of its infectious disease unit. |
|
|
|
By Annalee Armstrong Blueprint Medicines’ solid tumor med BLU-222 is back from the drawing board after the FDA lifted a partial clinical hold that has been in place since mid-February. |
By James Waldron AstraZeneca has pulled out of a pneumonia collaboration with Aridis Pharmaceuticals, sending the biotech’s phase 3 plans into a tailspin over the company’s alleged failure to hand over the agreed upfront payment two years ago. |
By Nick Paul Taylor Cash constraints are forcing Corvus Pharmaceuticals to clip the wings of its lead candidate. Rather than advance on multiple fronts, the biotech is focusing on cancers including T-cell lymphoma and holding off on starting a phase 1 trial in atopic dermatitis. |
By James Waldron With 2023 shaping up to be defined by biotech-on-biotech mergers, Infinity Pharmaceuticals’ announcement in February that it was planning to merge with MEI Pharma didn’t raise too many eyebrows. But Infinity has now revealed that the proposed combination could be the company’s last hope of staying afloat. |
By Nick Paul Taylor Satsuma Pharmaceuticals is hunkering down while searching for a savior. After opting against trying to commercialize a migraine candidate itself, the biotech has outlined plans to lay off 36% of its employees to eke out its cash ahead of a planned strategic transaction. |
By Annalee Armstrong EQT Life Sciences’ LSP Dementia Fund has flown past its target raise to reach 260 million euros ($281.8 million), which will go on to support 10 to 15 companies working in neurodegeneration. |
By Max Bayer Viking Therapeutics is riding positive investor feedback after its dual GLP-1/GIP agonist posted encouraging phase 1 results as a weight loss treatment. The company says it plans to launch a phase 2 trial in the middle of the year. |
By Teresa Carey This week on "Podnosis," we discuss the public health repercussions of the Ohio train derailment in East Palestine. We also talk about how data analytics can complement screening for social determinants of health. |
By Fraiser Kansteiner While commercial revenue has yet to materialize in bluebird bio's earnings report, the company is flying high on the U.S. launches of its two new gene therapies Zynteglo and Skysona. |
By Andrea Park The FDA's new cybersecurity requirements went live Wednesday, as a $1.7 trillion federal omnibus spending bill took effect. |
By Paige Minemyer The NCAA basketball tournament is officially underway, and that means the Fierce Healthcare team is back with another bracket competition as well. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ Connect with senior executives in Medical Affairs, MSL and IIT to share best practices. Register Today & save $200 from now until April 7th!
|
|
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperThis paper describes the key elements of good US/EU corporate governance for US-based biopharma companies in operating Europe. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
